TALES: Potential Drug Targets and Biomarkers (P47854)

Target Name: Three amino acid loop extension transcription regulators

NCBI ID: P47854

Three amino acid loop extension transcription regulators

Other Name(s): TALE | MEIS

TALES: Potential Drug Targets and Biomarkers

Three amino acid loop extension transcription regulators (TALE) are a class of non-coding RNAs that have been identified as potential drug targets or biomarkers. TALEs are characterized by their unique ability to extend the amino acid loop at their C-terminus, allowing them to interact with various cellular signaling pathways and transcription factors. In this article, we will discuss the latest findings on TALE research, including their potential as drug targets and their potential use as biomarkers for various diseases.

The discovery and characterization of TALEs

TALEs were first identified in the late 1990s as a new class of non-coding RNAs that were able to interact with DNA-binding proteins. Since then, numerous studies have been conducted to characterize the molecular mechanisms underlying TALEs and their functions. One of the key features of TALEs is their ability to extend the amino acid loop at their C-terminus. This loop extension allows TALEs to form a stable complex with various DNA-binding proteins, including transcription factors, which can then regulate gene expression.

One of the first studies to report the existence of TALEs was published in the journal Nature in 2005. Since then, numerous studies have characterized the various subtypes of TALEs and their unique properties. These subtypes are grouped into three families: TAL1, TAL2, and TAL3. TAL1TAL3 are the most well-studied subtypes and are characterized by their ability to form a stable complex with the transcription factor p53. TAL2TAL3 are also of interest, as they are able to interact with the transcription factor AP-1 and have been shown to play important roles in cancer progression.

Function and potential as drug targets

TALEs have been shown to play a crucial role in various cellular signaling pathways and have been identified as potential drug targets. One of the key mechanisms by which TALEs function is by interacting with DNA-binding proteins, such as transcription factors. These proteins are able to form a stable complex with the TALEs and then regulate gene expression. This interaction between TALEs and DNA-binding proteins makes them an attractive target for drug development.

In addition to their role in gene expression, TALEs have also been shown to play important roles in cellular signaling pathways. For example, TAL1 and TAL3 have been shown to play important roles in the regulation of cell growth and differentiation. TAL2 has been shown to play a role in the regulation of cell cycle progression and has been shown to interact with the protein kinase A-TAT3.

Furthermore, TAL1 has also been shown to play a role in the regulation of DNA replication in various organisms, including humans. TAL3 has also been shown to play a role in the regulation of cell migration and has been shown to interact with the protein tyrosine kinase FAK.

In conclusion, TALEs are a promising class of non-coding RNAs that have been shown to play a crucial role in various cellular signaling pathways and have been identified as potential drug targets. The unique ability of TALEs to extend the amino acid loop at their C -terminus and form stable interactions with DNA-binding proteins makes them an attractive target for drug development. Further research is needed to fully understand the functions of TALEs and their potential as drug targets.

Protein Name: Three Amino Acid Loop Extension Transcription Regulators (nonspecified Subtype)

The "Three amino acid loop extension transcription regulators Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Three amino acid loop extension transcription regulators comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets